Bausch + Lomb (NYSE:BLCO) Earns In-Line Rating from Evercore ISI

Bausch + Lomb (NYSE:BLCO)‘s stock had its “in-line” rating reiterated by investment analysts at Evercore ISI in a research report issued on Monday, Marketbeat.com reports. They presently have a $18.00 target price on the stock. Evercore ISI’s price objective would indicate a potential upside of 5.05% from the stock’s current price.

Several other analysts have also weighed in on the stock. Royal Bank Of Canada raised their price objective on shares of Bausch + Lomb from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bausch + Lomb in a research report on Wednesday, October 8th. Wells Fargo & Company raised their price target on Bausch + Lomb from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Friday, November 14th. HC Wainwright lifted their price objective on Bausch + Lomb from $16.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, JPMorgan Chase & Co. increased their target price on Bausch + Lomb from $13.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, October 30th. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $17.00.

Bausch + Lomb Stock Performance

Shares of NYSE:BLCO opened at $17.14 on Monday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.51 and a quick ratio of 0.98. The business’s fifty day moving average price is $16.29 and its two-hundred day moving average price is $15.08. Bausch + Lomb has a fifty-two week low of $10.45 and a fifty-two week high of $18.34. The stock has a market capitalization of $6.07 billion, a price-to-earnings ratio of -19.70, a price-to-earnings-growth ratio of 0.98 and a beta of 0.61.

Bausch + Lomb (NYSE:BLCO) last issued its earnings results on Wednesday, October 29th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.16 by $0.02. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.28 billion. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.13 EPS. As a group, analysts predict that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Institutional Trading of Bausch + Lomb

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its stake in shares of Bausch + Lomb by 428.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 299,671 shares of the company’s stock valued at $4,345,000 after purchasing an additional 242,993 shares during the period. Oaktree Capital Management LP acquired a new stake in shares of Bausch + Lomb during the second quarter worth $32,801,000. Vident Advisory LLC bought a new stake in Bausch + Lomb in the first quarter valued at about $289,000. Handelsbanken Fonder AB acquired a new position in Bausch + Lomb in the second quarter valued at about $202,000. Finally, Goldentree Asset Management LP lifted its stake in Bausch + Lomb by 14.9% in the second quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock valued at $33,524,000 after buying an additional 334,916 shares during the period. 11.07% of the stock is owned by institutional investors.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.